The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AE | Indole derivatives |
| Code | Title | |
|---|---|---|
| N05AE01 | Oxypertine | |
| N05AE02 | Molindone | |
| N05AE03 | Sertindole | |
| N05AE04 | Ziprasidone | |
| N05AE05 |
| Active Ingredient | Description | |
|---|---|---|
| Lurasidone |
Lurasidone is a selective blocking agent of dopamine and monoamine effects indicated for the treatment of schizophrenia. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7 receptors. Lurasidone does not bind to histaminergic or muscarinic receptors. |
|
| Oxypertine |
|
|
| Sertindole |
|
|
| Ziprasidone |
Ziprasidone has been shown to be an antagonist at both serotonin type 2A (5HT2A) and dopamine type 2 (D2) receptors. It is proposed that the therapeutic activity is mediated, in part, through this combination of antagonist activities. Ziprasidone is also a potent antagonist at 5HT2C and 5HT1D receptors, a potent agonist at the 5HT1A receptor and inhibits neuronal reuptake of norepinephrine and serotonin. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GEODON Capsule, hard | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| GEODON Powder for solution for injection | Web Search | MPI, EU: SmPC | |
| LATUDA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZELDOX Capsule | Health Products and Food Branch (CA) | MPI, CA: SPM |
